Released on = May 29, 2007, 1:06 pm

Press Release Author = Princeton Research

Industry = Biotech

Press Release Summary = Biotechnology developer of natural anti inflammatory
pharmaceuticals, Metabolic Research Inc. (Stock Symbol: MTBR), acquires
biotechnology products marketing company and the proprietary technologies of a
metabolic drug development company to accelerate development and sales of their
natural biotechnology developed pharmaceuticals products.

Press Release Body = Las Vegas, Nevada - May 30, 2007 - In biotechnology stock news,
developer of natural anti inflammatory pharmaceutical products, Metabolic Research
Inc. (Stock Symbol MTBR), announces two significant acquisitions.

You can visit http://www.princetonresearch.com/mtbr.htm for stock quotes and more
information.

On May 23 Metabolic Research (MTBR corporate web site: www.metabolicresearchinc.com)
acquired IDZIN, Inc. a biotechnology marketing company with proprietary software,
strong Internet presence and logistics facilities. IDZIN has profitable cash flow
and they will become a wholly owned subsidiary of Metabolic Research (MTBR). In
addition IDZIN has established relationships with decision makers at target market
companies, and they have developed a marketing system that addresses Metabolic\'s
primary target markets.

\"This transaction will further accelerate our profitable entry into the market,\"
said Dr. David Summers, Chairman and CEO. \"The IDZIN customer base will propel sales
of our line of dynamic state-of-the-art, natural, bio-identical,
pharmaceutical-grade products.

On May 16 Metabolic Research (MTBR) acquired principal assets relating to
metabolically engineered drug development, formulas, prototypes, packaging design
and marketing rights from Partners in Science Holdings, Inc. The acquisition was
completed through an \"all stock\" transaction utilizing restricted common shares of
the Company.

Metabolic Research plans to utilize this technology to further its research and
development of a new form of natural anti-inflammatory and analgesic products, both
pharmaceuticals and nutraceuticals, for the treatment of arthritis and other
inflammatory diseases.

Included in the purchase are 15 product formulations, branding for four
trademarks/trade names, six provisional patent applications, two technologies ready
for patent filing, three contract executives, and one marketing contract, all of
which should enable MTBR to enter the market during the current quarter.

\"This transaction should accelerate Metabolic Research\'s path to profitability. We
are a fully reporting OTC company with a complete line of dynamic state-of-the-art
products tailored to a dramatically growing demand for natural, bio-identical,
pharmaceutical grade products. We have no debt, a positive balance sheet, and funds
committed to take us into profitability. This acquisition should prove to be the
catalyst we need to quickly move from the R&D phase into one where we realize
increasing revenues and profits, thus building long-term equity for our
shareholders,\" says Dr. David Summers, D.Sc., Ph.D., Chief Executive Officer of
Metabolic Research, Inc.

About Metabolic Research, Inc.:

Changing the way drugs are grown, Metabolic Research (MTBR) is a biotechnology
company developing a new form of pharmaceutical grade non-synthetic pharmaceuticals
aimed to safely and effectively treat arthritis, heart disease and metabolic and
inflammatory diseases. MRI\'s proprietary process is based on \"growing\" drugs by
using natural metabolic processes of plants or fungus rather than chemical synthesis
used by traditional pharmaceutical companies.
Although the company plans to use the Agaricus blazei Murril mushroom, this process
is compatible to any fungal species. The company\'s research in metabolic
pharmaceuticals is in its initial phases, and preliminary research suggests this
process could be used to develop safe and highly effective naturally produced
pharmaceutical-grade anti-inflammatory, anti-infective and anti-viral substances to
fight a broad range of diseases.

Metabolic Research, Inc. has recently acquired a license for two provisional patents
\"Composition and Method of Producing Endogenous Therapeutic Anti-Inflammatory
Eiconasids and their Metabolites by Exogenous or Oral Means,\" and \"Method and
Process for Producing Anti-inflammatory Products from Fungi.\"

MRI\'s short-term game plan calls for using these patents to develop a natural drug
to effectively treat arthritis.

MRI has just teamed up in a strategic alliance, one of the goals of which is to
effectively develop a natural drug for cancer treatment.



This press release may include \"forward-looking statements\" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Although the Company believes that the
expectations reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such forward-looking
statements will prove to have been correct. The Company\'s actual results could
differ materially from those anticipated in the forward-looking statements. The
Company refers you to the cautionary statements and risk factors set forth in the
documents it files with the Securities and Exchange Commission. Neither the Company
or Princeton Research is under any obligation (and expressly disclaims any
obligation) to update or alter its forward-looking statements, whether as a result
of new information, future events, or otherwise.


Web Site = http://www.princetonresearch.com/mtbr.htm

Contact Details = Princeton Research, Inc.
Mike King
702-650-3000
3887 Pacific Street
Las Vegas, NV 89121
mike@princetonresearch.com